Imatinib trough levels have been associated with its clinical effects. During chronic use of imatinib, CYP2C8 becomes an important metabolizing enzyme because of cytochrome P450 3A4 (CYP3A4) autoinhibition. Single nucleotide polymorphisms (SNPs) in CYP2C8 may affect imatinib trough levels. This study investigates the effect of common CYP2C8 polymorphisms [∗1B (rs7909236), ∗1C (rs17110453), ∗3 (rs11572080 and rs10509681), and ∗4 (rs1058930)] on steady-state trough levels imatinib during chronic imatinib use in 43 patients with chronic myeloid leukemia or gastrointestinal stromal tumors. Standardized imatinib trough levels did not show a significant difference between wild-Type and variant groups for any of the tested SNPs, but an association with age was found, with older patients having higher trough levels. This suggests that common CYP2C8 SNPs have no effect on the pharmacokinetics of imatinib.

, , , , , , ,,
Pharmacogenetics and Genomics
Erasmus MC: University Medical Center Rotterdam

Verboom, M., Visser, L., Kouwen, S. (Sander), Swen, J., Diepstraten, J. (Jeroen), Posthuma, W., … Wilms, E. (2017). Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenetics and Genomics, 27(6), 223–226. doi:10.1097/FPC.0000000000000278